Evidence map›Paper›PMID 37552372›Full record

ArticleAnnals of intensive care2023

Overview of the current use of levosimendan in France: a prospective observational cohort study.

Bernard Cholley, Mirela Bojan, Benoit Guillon, Emmanuel Besnier, Mathieu Mattei, Bruno Levy, Alexandre Ouattara, Nadir Tafer, Clément Delmas, David Tonon and 8 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of intensive care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 1 country.

Bernard CholleyDepartment of Anaesthesiology and Intensive Care Medicine, Hôpital Européen Georges Pompidou, AP-HP, 75015, Paris, France. bernard.cholley@aphp.fr.ORCID http://orcid.org/0000-0001-6388-6011
Mirela BojanPôle Cardiopathies Congénitales, Hôpital Marie Lannelongue, Groupe Hospitalier Paris-Saint Joseph, 92350, Le Plessis-Robinson, France.
Benoit GuillonDepartment of Cardiology, University Hospital Besancon, Besançon, France.
Emmanuel BesnierDepartment of Anaesthesiology and Critical Care, Normandie Univ, UNIROUEN, INSERM U1096, CHU Rouen, 76000, Rouen, France.
Mathieu MatteiDepartment of Cardiology and Cardiac Surgery, CHRU de Nancy, Hôpital de Brabois, Vandoeuvre-les Nancy, France.
Bruno LevyCHRU Nancy, Critical Care, CHRU de Nancy, Hôpital de Brabois, Vandoeuvre-Les Nancy, France.
Alexandre OuattaraDepartment of Cardiovascular Anesthesia and Critical Care, CHU Bordeaux, CHU de Bordeaux, 33000, Bordeaux, France.
Nadir TaferDepartment of Cardiovascular Anesthesia and Critical Care, CHU Bordeaux, CHU de Bordeaux, 33000, Bordeaux, France.
Clément DelmasCardiology Department, Rangueil University Hospital, Toulouse, France.
David TononDepartment of Anaesthesiology and Critical Care Medicine, University Hospital Timone, AP-HM, Aix-Marseille University, 13385, Marseille CEDEX 05, France.
Bertrand RozecDepartment of Anaesthesiology and Critical Care, Institut du Thorax, Laennec Hospital, CHU de Nantes, and Nantes Université, CHU Nantes*, CNRS, INSERM, 44000, Nantes, France.
Jean-Luc FellahiDepartment of Cardiothoracic Anaesthesiology and Critical Care, Louis Pradel University Hospital, Lyon, France.
Pascal LimCardiology department, Henri-Mondor University Hospital, AP-HP, Créteil, France.
François LabasteDepartment of Anaesthesiology and Critical Care Medicine, Rangueil University Hospital, Toulouse, France.
François RoubilleCardiology Department INI-CRT PhyMedExp INSERM, CNRS CHU de Montpellier, Université de Montpellier, Montpellier, France.
Thibaut CarubaDepartment of Pharmacy, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
Philippe MauriatDepartment of Cardiovascular Anesthesia and Critical Care, CHU Bordeaux, CHU de Bordeaux, 33000, Bordeaux, France.
ARCOTHOVA study group
Centre Hospitalier Régional et Universitaire de Nancy · FRCentre National de la Recherche Scientifique · FRUniversité de Bordeaux · FRAssistance Publique – Hôpitaux de Paris · FRHôpital Rangueil · FRInserm · FRAix-Marseille Université · FRCentre Hospitalier Universitaire de Besançon · FRCentre Hospitalier Universitaire de Bordeaux · FRHôpital Marie Lannelongue · FRHospices Civils de Lyon · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFollowing the results of randomized controlled trials on levosimendan, French health authorities requested an update of the current use and side-effects of this medication on a national scale.

methodThe France-LEVO registry was a prospective observational cohort study reflecting the indications, dosing regimens, and side-effects of levosimendan, as well as patient outcomes over a year.

resultsThe patients included (n = 602) represented 29.6% of the national yearly use of levosimendan in France. They were treated for cardiogenic shock (n = 250, 41.5%), decompensated heart failure (n = 127, 21.1%), cardiac surgery-related low cardiac output prophylaxis and/or treatment (n = 86, 14.3%), and weaning from veno-arterial extracorporeal membrane oxygenation (n = 82, 13.6%). They received 0.18 ± 0.07 µg/kg/min levosimendan over 26 ± 8 h. An initial bolus was administered in 45 patients (7.5%), 103 (17.1%) received repeated infusions, and 461 (76.6%) received inotropes and or vasoactive agents concomitantly. Hypotension was reported in 218 patients (36.2%), atrial fibrillation in 85 (14.1%), and serious adverse events in 17 (2.8%). 136 patients (22.6%) died in hospital, and 26 (4.3%) during the 90-day follow-up.

conclusionsWe observed that levosimendan was used in accordance with recent recommendations by French physicians. Hypotension and atrial fibrillation remained the most frequent side-effects, while serious adverse event potentially attributable to levosimendan were infrequent. The results suggest that this medication was safe and potentially associated with some benefit in the population studied.

Indexed as

Cardiogenic shockHeart failureInotropesLevosimendanRepetitive infusionsVA-ECMO weaning

Identifiers

PMID37552372
PMCPMC10409690
OpenAlexW4385661971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.